Walleye Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-13,712
Closed -$14K 5041
2024
Q4
$14K Buy
+13,712
New +$25.1K ﹤0.01% 4548
2023
Q2
Sell
-75,699
Closed -$133K 4831
2023
Q1
$133K Buy
75,699
+5,893
+8% +$16.8K ﹤0.01% 2763
2022
Q4
$219K Sell
69,806
-26,009
-27% -$101K ﹤0.01% 1977
2022
Q3
$469K Buy
95,815
+74,747
+355% +$384K 0.01% 1528
2022
Q2
$87K Sell
21,068
-62,905
-75% -$272K ﹤0.01% 1769
2022
Q1
$488K Buy
+83,973
New +$499K 0.01% 1024
2021
Q4
Sell
-11,465
Closed -$103 2291
2021
Q3
$103 Buy
+11,465
New +$113K ﹤0.01% 1333
2021
Q1
Sell
-26,700
Closed -$417 1327
2020
Q4
$417 Buy
+26,700
New +$313K 0.03% 532
2019
Q3
Sell
-22,699
Closed -$244K 2234
2019
Q2
$244K Buy
22,699
+21,599
+1,964% +$230K 0.03% 858
2019
Q1
$10K Buy
+1,100
New +$11.2K ﹤0.01% 1405

Other funds holding SGMO

Walleye Capital's SGMO Position: Q1 2025 in Review

Walleye Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 13,712 shares — an estimated $14K sold.

Walleye Capital first reported a position in SGMO in Q1 2019 and held it in 10 quarters. The position peaked at $488K in Q1 2022. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Walleye Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 13,712 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $14K.
  • Walleye Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2019 and held it in 10 quarters.
  • Walleye Capital's SANGAMO THERAPEUTICS INC position peaked at $488K in Q1 2022.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.